Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015 | View Paper
“ GEM therapy reduced significantly the level of the CA 19-9 tumor marker, and diagnostic imaging allowed a judgment of partial response or stable disease after 18 months.”
Gan to kagaku ryoho. Cancer & chemotherapy • 2012 | View Paper
“Both patients showed a significant elevation of pretreatment CA 19-9 levels (7,505 and 150,000 U/ml, respectively), however, subsequently they experienced a highly significant reduction (>90%) of CA 19-9 kinetics under gemcitabine chemotherapy.”
Oncology Research and Treatment • 2007 | View Paper
“ResultsPatients with advanced … adenocarcinoma receiving gemcitabine who experienced a decrease of ≥20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2–23.5) compared to 7.6+ months (range 4.0–14.7) in those without such a change (p = 0.0109).”
Journal of gastrointestinal cancer • 2007 | View Paper
“In conclusion, a decrease of CA 19–9 > 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer.”